Corvus shares surge on strong eczema data despite Q4 miss
$189M financing extends runway to 2028 as Phase 2 trial begins
Corvus Pharmaceuticals shares jumped on Wednesday as investors looked past a quarterly earnings miss to focus on positive Phase 1 clinical data for the company's eczema treatment and a substantial financing that extends the company's cash runway through 2028.
The clinical-stage biopharmaceutical company reported a fourth-quarter loss of 15 cents per share, missing analyst expectations of a 13.5-cent loss, according to market data. However, the company's soquelitinib treatment for atopic dermatitis demonstrated what analysts called impressive efficacy results in its Phase 1 trial, with 75% of treated patients achieving EASI 75—the standard measure of 75% improvement in eczema symptoms—compared to just 20% in the placebo group.
The results, which showed deepening responses over an eight-week treatment period, included 25% of patients reaching EASI 90 and 33% achieving an Investigator Global Assessment score of 0 or 1, with no placebo patients reaching these thresholds. Building on positive data from earlier cohorts, Corvus initiated a Phase 2 trial in the first quarter of this year targeting approximately 200 patients with moderate-to-severe atopic dermatitis who have failed prior therapies.
"We are excited to report this positive data from the Phase 1 trial of soquelitinib in atopic dermatitis," Corvus said in a statement, noting that the Phase 2 program will evaluate the drug in patients who have previously received systemic therapy, addressing a significant unmet medical need.
The financial strength behind the clinical progress comes from a public offering completed in January that raised $189.4 million in net proceeds, extending Corvus's cash runway into the second quarter of 2028. The company ended 2025 with $56.8 million in cash, cash equivalents, and marketable securities, up from $52.0 million at year-end 2024.
Research and development expenses increased to $9.9 million in the fourth quarter, up from $6.0 million in the same period last year, primarily reflecting increased clinical trial and manufacturing costs for soquelitinib. The company posted a net loss of $12.3 million for the quarter, compared to $12.1 million in the prior year.
Beyond atopic dermatitis, Corvus is advancing soquelitinib across multiple indications. The drug received Orphan Drug Designation and Fast Track designation from the FDA for treating T-cell lymphoma, with a Phase 3 registrational trial currently enrolling patients. Final Phase 1/1b data showed median progression-free survival of 6.2 months and median overall survival of 28.1 months in the 200 mg twice-daily cohort. The company is also conducting a Phase 2 trial for Autoimmune Lymphoproliferative Syndrome in collaboration with the National Institute of Allergy and Infectious Diseases.
Analysts remain bullish on Corvus's prospects, with a consensus target price of $35 representing 119% upside from current levels, according to market data. The stock currently trades at $16.01 with a market capitalization of approximately $1.4 billion. The shares have a 52-week range of $2.54 to $26.95, reflecting significant volatility typical of clinical-stage biopharmaceutical companies.
The broader atopic dermatitis market represents a substantial opportunity, with millions of patients worldwide seeking alternatives to existing treatments. Major pharmaceutical companies have invested heavily in the space, and the efficacy results from soquelitinib position Corvus as a potential competitor in a market that analysts estimate could reach tens of billions of dollars annually.
Investors will be watching for data readouts from the ongoing Phase 2 trial, which could begin to emerge in late 2026 or early 2027, as well as progress in the T-cell lymphoma Phase 3 study. The company's partner in China, Angel Pharmaceuticals, is also conducting a Phase 1b/2 clinical trial for atopic dermatitis, with initial results anticipated later this year.